Rheumatoid arthritis trials in Poland

In Poland 20 Also abroad 351

20 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA)
Where
Cracow, Jozefow, Poznan, Warsaw
Age
18 years and over
People
56 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to join2024-519114-31-00 · EU 2024-519114-31-00
Phase 1Taking people
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immune response in humans
Where
Warsaw
Age
18 years and over
People
76 worldwide
Run by
Jjp Biologics Sp. z o.o.
See details and how to join2023-508661-33-00 · EU 2023-508661-33-00
Phase 3Not yet taking people in Poland
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
Where
Bydgoszcz, Nadarzyn, Olsztyn, Plonsk, Tomaszów Lubelski, Warsaw, Wroclaw, ZDROWIE OSTEO-MEDIC S.C. L. i A. Racewicz, A. i J. Supronik
Age
18 years and over
People
266
Run by
Celltrion Inc.
See details and how to join2026-526538-15-00 · EU 2026-526538-15-00
Phase 1/2Taking people
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
Where
Jozefow
Age
18 years to 65 years
People
84 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07412704 · EU 2025-520666-22-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Where
Bytom, Elbl?g, Krakow, Lublin, Nowa Sól, Warsaw, Wroclaw
Age
18 years and over
People
160 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07137598
Phase 2Taking people
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
Where
Bytom, Elblag, Lublin, Nowa Sol, Warsaw, Wroclaw
Age
18 years and over
People
120 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07620392 · EU 2025-523579-47-00
Phase 1Not yet taking people in Poland
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Bydgoszcz, Krakow, Poznan
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 2Taking people
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Where
Krakow, Torun, Warsaw, Wroclaw
Age
18 years and over
People
320 worldwide
Run by
AstraZeneca
See details and how to joinNCT07276581
Phase 2Taking people
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Where
Bydgoszcz, Cracow, Elblag, Olsztyn, Warsaw
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT06972446 · EU 2025-520721-21-00
Phase 2Taking people
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
Where
Cracow, Torun, Warsaw, Wroclaw
Age
18 years and over
People
97 worldwide
Run by
AstraZeneca AB
See details and how to join2025-522076-85-00 · EU 2025-522076-85-00
Phase 1Taking people
Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
Where
Torun, Warsaw
Age
18 years to 75 years
People
176 worldwide
Run by
Lifordi Immunotherapeutics, Inc.
See details and how to joinNCT07207954
Phase 2Not yet taking people in Poland
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
Where
Bialystok, Cracow, Katowice, Łódź, Lublin, Oswiecim, Poznan, Sosnowiec, Warsaw, Wroclaw
Age
18 years and over
People
95 worldwide
Run by
Elevara Medicines Limited
See details and how to join2025-524005-32-00 · EU 2025-524005-32-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or who Cannot Tolerate TNF and/or JAK Inhibitors
Where
Bytom, Elblag, Lublin, Nowa Sol, Warsaw, Wroclaw
Age
18 years and over
People
89 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2025-521034-28-00 · EU 2025-521034-28-00
Phase 1Taking people
A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis
Where
Torun, Warsaw
Age
18 years and over
People
40
Run by
Lifordi Immunotherapeutics Inc.
See details and how to join2025-523409-13-00 · EU 2025-523409-13-00
No phaseTaking people
Integrative AI-Based Multiomic and Neurophysiological Profiling of Chronic Pain in Rheumatoid Arthritis
Where
Wroclaw
Age
18 years and over
People
100
Run by
4th Military Clinical Hospital with Polyclinic, Poland
See details and how to joinNCT07769619
Phase 1Taking people
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
Where
Jozefow
Age
18 years to 64 years
People
15 worldwide
Run by
Neurocrine Biosciences Inc.
See details and how to join2025-525113-22-00 · EU 2025-525113-22-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bydgoszcz, Lodz, Warsaw
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Bytom, Gdansk, Gliwice, Lodz
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Cracow, Poznan, Warsaw
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 2Taking people
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
Where
Chorzów, Katowice, Poznan, Swidnica
Age
18 years and over
People
240 worldwide
Run by
SynAct Pharma Aps
See details and how to joinNCT06671054